نتایج جستجو برای: skbr3

تعداد نتایج: 420  

2016
Ling-Jun Zhao Paul M. Loewenstein Maurice Green

Human cancers frequently arise from increased expression of proto-oncogenes, such as MYC and HER2. Understanding the cellular pathways regulating the transcription and expression of proto-oncogenes is important for targeted therapies for cancer treatment. Adenoviral (Ad) E1A 243R (243 aa residues) is a viral oncoprotein that interacts with key regulators of gene transcription and cell prolifera...

2000
Xiao-Feng Le Ratna Vadlamudi Amanda McWatters Duk Soo Bae Gordon B. Mills Rakesh Kumar Robert C. Bast

To understand the molecular mechanisms by which anti-p185 antibody and the ligand heregulin inhibit tumor growth, we have investigated several signaling proteins and pathways. We report here that anti-p185 monoclonal antibody ID5 induced tyrosine phosphorylation of HER2 in SKBr3 breast cancer cells that overexpress p185. Heregulin b1 induced phosphorylation of both HER3 and HER2. ID5 produced a...

Journal: :Endocrine-related cancer 2005
B Brandt D Kemming J Packeisen R Simon M Helms U Feldmann A Matuschek C Kersting B Hinrichs J-M Bidart D Bellet K Bartkowiak N Dankbar T Dittmar G Sauter W Boecker H Buerger

Early placenta insulin-like growth factor (EPIL) is expressed by a subpopulation of the Her2-positive SKBR3 breast cancer cell line displaying high motility and transendothelial invasiveness in vitro, as recently shown by our group. As a consequence of this, we established cellular models by generating an EPIL-overexpressing SKBR3 cell line, knocked down EPIL by adding specific small interferin...

Journal: :International journal of cancer 2004
Yuhong Lu Xiaolin Zi Michael Pollak

The clinical usefulness of trastuzumab (Herceptin; Genentech, San Francisco, CA) in breast cancer treatment is limited by the rapid development of resistance. We previously reported that IGF-I signaling confers resistance to the growth-inhibitory actions of trastuzumab in a model system, but the underlying molecular mechanism remains unknown. We used SKBR3/neo cells (expressing few IGF-I recept...

اشتری, پرویز, حسنوند, محمد, علیرضاپور, بهروز, کشاورزی, فاطمه,

مقدمه: نانوذرات مغناطیسی به عنوان گروهی از مواد نانو مقیاس، انقلاب عظیمی را در روش ­های تشخیص و درمان در دانش پزشکی ایجاد کرده ­اند. نیمه عمر مناسب رادیوایزوتوپ ایندیم-111 باعث شده تا این رادیوایزوتوپ برای مطالعات داخل بدن، مورد استفاده قرار گیرد. در این پژوهش، در ابتدا تهیه کمپلکس رادیو­ داروی ایندیم-۱۱۱ با نانوذرات مغناطیسی سیلیکات(Fe3O4@SiO2)، جهت به دست آوردن شرایط بهینه جذب و پایداری، مورد...

2015
Mousumi Majumder Erin Landman Ling Liu David Hess Peeyush K. Lala

MicroRNAs (miRs) are small regulatory molecules emerging as potential biomarkers in cancer. Previously, it was shown that COX-2 expression promotes breast cancer progression via multiple mechanisms, including induction of stem-like cells (SLC), owing to activation of the prostaglandin E2 receptor EP4 (PTGER4). COX-2 overexpression also upregulated microRNA526b (miR-526b), in association with ag...

2017
Ming Zhao Erin W. Howard Amanda B. Parris Zhiying Guo Qingxia Zhao Zhikun Ma Ying Xing Bolin Liu Susan M. Edgerton Ann D. Thor Xiaohe Yang

Lapatinib, a small molecule ErbB2/EGFR inhibitor, is FDA-approved for the treatment of metastatic ErbB2-overexpressing breast cancer; however, lapatinib resistance is an emerging clinical challenge. Understanding the molecular mechanisms of lapatinib-mediated anti-cancer activities and identifying relevant resistance factors are of pivotal significance. Cancerous inhibitor of protein phosphatas...

2016
Jianzong Li Haiyang Wang Junjie Li Jinku Bao Chuanfang Wu

Breast cancer is one of the most lethal types of cancer in women worldwide due to the late stage detection and resistance to traditional chemotherapy. The human epidermal growth factor receptor 2 (HER2) is considered as a validated target in breast cancer therapy. Even though a substantial effort has been made to develop HER2 inhibitors, only lapatinib has been approved by the U.S. Food and Dru...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید